CD96 and central nervous system cancer: We concluded that CD96 was highly involved in the various immune responses and infiltration, shedding light to a new avenue where immunotherapies combining CD96 blockade and existing checkpoint inhibitors might be a feasible approach to suppressing these unpleasing tumors, especially gliomas in which CD96 is a distinctive risk factor.